Proportions of patients with fast eGFR decline (mean annual decrease of eGFR ≥3 mL/min/1.73 m2/year), by treatment arm
| . | Baseline to 4 years . | . | 6 months to 4 years . | . | ||
|---|---|---|---|---|---|---|
| . | Dapagliflozin . | Placebo . | P value . | Dapagliflozin . | Placebo . | P value . |
| Subgroup . | n/N (%) . | n/N (%) . | n/N (%) . | n/N (%) . | ||
| Overall | 2,724/8,096 (33.7) | 2,961/8,012 (37.0) | <0.0001 | 2,041/7,603 (26.8) | 2,747/7,409 (37.1) | <0.0001 |
| Demographic characteristics | ||||||
| Age, <65 years | 1,436/4,380 (32.8) | 1,560/4,355 (35.8) | 0.0028 | 1,104/4,149 (26.1) | 1,417/4,041 (35.1) | <0.0001 |
| Age, ≥65 years | 1,288/3,716 (34.7) | 1,401/3,657 (38.3) | 0.0011 | 937/3,454 (27.1) | 1,330/3,368 (39.5) | <0.0001 |
| Medical History | ||||||
| Duration of diabetes (years) | ||||||
| ≤10 | 1,298/4,030 (32.2) | 1,441/4,053 (35.6) | 0.0015 | 1,021/3,805 (26.8) | 1,355/3,756 (36.1) | <0.0001 |
| >10 | 1,426/4,066 (35.0) | 1,520/3,958 (38.4) | 0.0020 | 1,020/3,798 (26.9) | 1,392/3,653 (38.1) | <0.0001 |
| History of hypertension | ||||||
| Yes | 2,509/7,327 (34.2) | 2,693/7,150 (37.7) | <0.0001 | 1,865/6,890 (27.1) | 2,512/6,604 (38.0) | <0.0001 |
| No | 215/769 (28.0) | 268/862 (31.1) | 0.1657 | 176/713 (24.7) | 235/805 (29.2) | 0.0478 |
| Laboratory and clinical measurements | ||||||
| Baseline HbA1c | ||||||
| <9%/75 mmol/mol | 1,877/5,940 (31.6) | 2,128/5,994 (35.5) | <0.0001 | 1,425/5,600 (25.5) | 1,996/5,567 (35.9) | <0.0001 |
| ≥9%/75 mmol/mol | 847/2,154 (39.3) | 833/2,014 (41.4) | 0.1800 | 616/2,001 (30.8) | 750/1,839 (40.8) | <0.0001 |
| Baseline eGFR (mL/min/1.73m2) | ||||||
| <60 | 144/555 (26.0) | 162/592 (27.4) | 0.5869 | 122/493 (24.8) | 193/532 (36.3) | <0.0001 |
| 60 to <90 | 1,345/3,614 (37.2) | 1,472/3,636 (40.5) | 0.0043 | 1,070/3,395 (31.5) | 1,452/3,358 (43.2) | <0.0001 |
| ≥90 | 1,235/3,927 (31.5) | 1,327/3,784 (35.1) | 0.0007 | 848/3,714 (22.8) | 1,102/3,519 (31.3) | <0.0001 |
| Baseline UACR (mg/g) | ||||||
| Below detectable to <15 | 1,207/4,298 (28.1) | 1,316/4,261 (30.9) | 0.0045 | 954/4,061 (23.5) | 1,288/3,999 (32.2) | <0.0001 |
| 15 to <30 | 416/1,212 (34.3) | 446/1,209 (36.9) | 0.1871 | 303/1,144 (26.5) | 419/1,106 (37.9) | <0.0001 |
| ≥30 to ≤300 | 757/1,898 (39.9) | 800/1,864 (42.9) | 0.0588 | 548/1,779 (30.8) | 718/1,712 (41.9) | <0.0001 |
| >300 | 294/548 (53.7) | 345/528 (65.3) | <0.0001 | 201/496 (40.5) | 272/461 (59.0) | <0.0001 |
| KDIGO risk categories | ||||||
| Low risk | 1,562/5,204 (30.0) | 1,703/5,150 (33.1) | 0.0008 | 1,197/4,929 (24.3) | 1,616/4,814 (33.6) | <0.0001 |
| Moderate risk | 769/2,001 (38.4) | 803/1,965 (40.9) | 0.1170 | 569/1,877 (30.3) | 737/1,807 (40.8) | <0.0001 |
| High/very high risk | 343/751 (45.7) | 401/747 (85.7) | 0.0019 | 239/673 (35.5) | 344/657 (52.4) | <0.0001 |
| Cardiovascular drugs—ACEi/ARB | ||||||
| Yes | 2,244/6,579 (34.1) | 2,475/6,529 (37.9) | <0.0001 | 1,686/6,197 (27.2) | 2,292/6,038 (38.0) | <0.0001 |
| No | 480/1,517 (31.6) | 486/1,483 (32.8) | 0.5078 | 355/1,406 (25.3) | 455/1,371 (33.2) | <0.0001 |
| . | Baseline to 4 years . | . | 6 months to 4 years . | . | ||
|---|---|---|---|---|---|---|
| . | Dapagliflozin . | Placebo . | P value . | Dapagliflozin . | Placebo . | P value . |
| Subgroup . | n/N (%) . | n/N (%) . | n/N (%) . | n/N (%) . | ||
| Overall | 2,724/8,096 (33.7) | 2,961/8,012 (37.0) | <0.0001 | 2,041/7,603 (26.8) | 2,747/7,409 (37.1) | <0.0001 |
| Demographic characteristics | ||||||
| Age, <65 years | 1,436/4,380 (32.8) | 1,560/4,355 (35.8) | 0.0028 | 1,104/4,149 (26.1) | 1,417/4,041 (35.1) | <0.0001 |
| Age, ≥65 years | 1,288/3,716 (34.7) | 1,401/3,657 (38.3) | 0.0011 | 937/3,454 (27.1) | 1,330/3,368 (39.5) | <0.0001 |
| Medical History | ||||||
| Duration of diabetes (years) | ||||||
| ≤10 | 1,298/4,030 (32.2) | 1,441/4,053 (35.6) | 0.0015 | 1,021/3,805 (26.8) | 1,355/3,756 (36.1) | <0.0001 |
| >10 | 1,426/4,066 (35.0) | 1,520/3,958 (38.4) | 0.0020 | 1,020/3,798 (26.9) | 1,392/3,653 (38.1) | <0.0001 |
| History of hypertension | ||||||
| Yes | 2,509/7,327 (34.2) | 2,693/7,150 (37.7) | <0.0001 | 1,865/6,890 (27.1) | 2,512/6,604 (38.0) | <0.0001 |
| No | 215/769 (28.0) | 268/862 (31.1) | 0.1657 | 176/713 (24.7) | 235/805 (29.2) | 0.0478 |
| Laboratory and clinical measurements | ||||||
| Baseline HbA1c | ||||||
| <9%/75 mmol/mol | 1,877/5,940 (31.6) | 2,128/5,994 (35.5) | <0.0001 | 1,425/5,600 (25.5) | 1,996/5,567 (35.9) | <0.0001 |
| ≥9%/75 mmol/mol | 847/2,154 (39.3) | 833/2,014 (41.4) | 0.1800 | 616/2,001 (30.8) | 750/1,839 (40.8) | <0.0001 |
| Baseline eGFR (mL/min/1.73m2) | ||||||
| <60 | 144/555 (26.0) | 162/592 (27.4) | 0.5869 | 122/493 (24.8) | 193/532 (36.3) | <0.0001 |
| 60 to <90 | 1,345/3,614 (37.2) | 1,472/3,636 (40.5) | 0.0043 | 1,070/3,395 (31.5) | 1,452/3,358 (43.2) | <0.0001 |
| ≥90 | 1,235/3,927 (31.5) | 1,327/3,784 (35.1) | 0.0007 | 848/3,714 (22.8) | 1,102/3,519 (31.3) | <0.0001 |
| Baseline UACR (mg/g) | ||||||
| Below detectable to <15 | 1,207/4,298 (28.1) | 1,316/4,261 (30.9) | 0.0045 | 954/4,061 (23.5) | 1,288/3,999 (32.2) | <0.0001 |
| 15 to <30 | 416/1,212 (34.3) | 446/1,209 (36.9) | 0.1871 | 303/1,144 (26.5) | 419/1,106 (37.9) | <0.0001 |
| ≥30 to ≤300 | 757/1,898 (39.9) | 800/1,864 (42.9) | 0.0588 | 548/1,779 (30.8) | 718/1,712 (41.9) | <0.0001 |
| >300 | 294/548 (53.7) | 345/528 (65.3) | <0.0001 | 201/496 (40.5) | 272/461 (59.0) | <0.0001 |
| KDIGO risk categories | ||||||
| Low risk | 1,562/5,204 (30.0) | 1,703/5,150 (33.1) | 0.0008 | 1,197/4,929 (24.3) | 1,616/4,814 (33.6) | <0.0001 |
| Moderate risk | 769/2,001 (38.4) | 803/1,965 (40.9) | 0.1170 | 569/1,877 (30.3) | 737/1,807 (40.8) | <0.0001 |
| High/very high risk | 343/751 (45.7) | 401/747 (85.7) | 0.0019 | 239/673 (35.5) | 344/657 (52.4) | <0.0001 |
| Cardiovascular drugs—ACEi/ARB | ||||||
| Yes | 2,244/6,579 (34.1) | 2,475/6,529 (37.9) | <0.0001 | 1,686/6,197 (27.2) | 2,292/6,038 (38.0) | <0.0001 |
| No | 480/1,517 (31.6) | 486/1,483 (32.8) | 0.5078 | 355/1,406 (25.3) | 455/1,371 (33.2) | <0.0001 |